At a glance
ClinicalIndex Comparison RecordN/ACompleted· 180 enrolled
Drug / intervention
Blood drawprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Human Liver Explants for HIF-1 Alpha- Analysis/Comparison
In Brief
An observational study evaluating Blood draw for Liver Cancer. Completed, enrolled 180 participants across 1 site.
Detailed Summary
The purpose of the study is to compare levels of HIF-1 α (Hypoxia Inducing Factor 1-alpha) in patients who have been treated with various types of liver cancer treatments.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLiver Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedMar 2009
Primary CompletionJul 2019
TodayJul 2026
First PostedMar 23, 2009
Enrollment StartFeb 1, 2006
Primary CompletionJul 1, 2019
TodayJul 2, 2026
Enrollment to primary: 13.4 yearsPosted 17.3 years ago
Interventions
Blood drawprocedure
A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).